Analysis of the CC chemokine receptor 5Δ32 polymorphism in pediatric liver transplant recipients

Pediatric Transplantation

Volumn 12, Issue 7, 2008, Pages 769-772

  Fischer Maas, Louise ^b   Schneppenheim, Reinhard ^c   Oyen, Florian ^c   Grabhorn, Enke ^b   Richter, Andrea ^b   Fischer, Lutz ^a   Ganschow, Rainer ^a,b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Pediatrics Hepatology   (Germany)

^c Pediatric Hematology and Oncology ^*  (Germany)

Author keywords

CCR5; Children; Graft dysfunction; Liver transplantation; Polymorphism

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CHEMOKINE RECEPTOR CCR5; CYCLOSPORIN A; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS;

ACUTE GRAFT REJECTION; ADOLESCENT; ARTICLE; BILE DUCT ATRESIA; CHILD; CHRONIC GRAFT REJECTION; DRUG DOSE REDUCTION; FEMALE; GENETIC ANALYSIS; GRAFT RECIPIENT; HETEROZYGOTE; HOMOZYGOTE; HUMAN; INFANT; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PROTEIN POLYMORPHISM; VANISHING BILE DUCT SYNDROME;

ADOLESCENT; BILIARY ATRESIA; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; LIVER DISEASES; LIVER TRANSPLANTATION; MALE; POLYMORPHISM, GENETIC; PRIMARY GRAFT DYSFUNCTION; RECEPTORS, CCR5;

EID: 53849124687     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2007.00900.x     Document Type: Article

References (22)

1. Hasenbein W, Albani J, Spehr A, et al. Long-term evaluation of cyclosporine and tacrolimus based immunosuppression in pediatric liver transplantation. Pediatr Transplant 2006 : 10 : 938 942.
2. Sanchez-Urdazpal L, Gores G, Ward E, et al. Ischemic-type biliary complications after orthotopic liver transplantation. Hepatology 1992 : 16 : 49 53.
3. Otto G, Roeren T, Golling M, et al. Ischemic type lesions of the bile ducts after liver transplantation: 2 years results. Zentralbl Chir 1995 : 120 : 450 454.
4. Murphy PM, Baggiolino M, Charo IF, et al. International union of pharmacology. XXII nomenclature for chemokine receptors. Pharmacol Rev 2000 : 52 : 145 176.
5. Nelson PJ, Krensky AM. Chemokines, chemokine receptors, and allograft rejection. Immunity 2001 : 14 : 377 386.
6. Wu L, Paxton WA, Kassam N, et al. CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1 in vitro. J Exp Med 1997 : 185 : 1681 1691.
7. Samson M, Libert F, Doranz BJ, et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR5 chemokine receptor gene. Nature 1996 : 382 : 722 725.
8. Moench C, Uhrig A, Lohse AW, Otto G. CC chemokine receptor 5Δ32 polymorphism - A risk factor for ischemic-type biliary lesions following orthotopic liver transplantation. Liver Transpl 2004 : 10 : 434 439.
9. Adams DH, Hubscher S, Fear J, et al. Hepatic expression of macrophage inflammatory protein-1 alpha and macrophage inflammatory protein-1 beta after liver transplantation. Transplantation 1996 : 61 : 817 825.
10. Mueller A, Strange PG. Molecules in focus: The chemokine receptor CCR5. Int J Biochem 2004 : 36 : 35 38.
11. Demetris AJ, Batts KP, Dhillon AP, et al. Banff schema for grading liver allograft rejection: An international consensus document. Hepatology 1997 : 25 : 658 663.
12. Fischereder M, Luckow B, Hocher B, et al. CC chemokine receptor 5 and renal transplant survival. Lancet 2001 : 357 : 1758 1761.
13. Schroppel B, Fischereder M, Ashkar R, et al. The impact of polymorphism in chemokine and chemokine receptors on outcomes in liver transplantation. Am J Transplant 2002 : 2 : 640 645.
14. Martin SR, Atkinson P, Anand R, et al. Studies of pediatric liver transplantation 2002: Patient and graft survival and rejection in pediatric recipients of a first liver transplant in the USA and Canada. Pediatr Transplant 2004 : 8 : 273 283.
15. Kim JS, Groteluschen R, Mueller T, et al. Pediatric transplantation: The Hamburg experience. Transplantation 2005 : 79 : 1206 1209.
16. Broering DC, Kim JS, Mueller T, et al. One hundred thirty-two consecutive pediatric liver transplants without hospital mortality. Ann Surg 2004 : 240 : 1002 1012.
17. Wiesner RH, Batts KP, Krom RA. Evolving concepts in the diagnosis, pathogenesis, and treatment of chronic hepatic allograft rejection. Liver Transpl Surg 1999 : 5 : 388 400.
18. Deshpande RR, Bowles MJ, Vilca-Melandes H, et al. Results of split liver transplantation in children. Ann Surg 2002 : 236 : 248 253.
19. Yun JJ, Whiting D, Fischbein MP, et al. Combined blockade of the chemokine receptors CCR1 and CCR5 attenuates chronic rejection. Circulation 2004 : 109 : 932 937.
20. Gao W, Faia KL, Csizmadia V, et al. Beneficial effects of targeting CCR5 in allograft recipients. Transplantation 2001 : 72 : 1199 1205.
21. Groene HJ, Weber C, Weber K, et al. Met-RANTES reduces vascular and tubular damage during acute renal transplant rejection: Blocking monocyte arrest and recruitment. FASEB J 1999 : 13 : 1371 1383.
22. Belperio JA, Burdick MD, Keane MP, et al. The role of the CC chemokine RANTES in acute lung allograft rejection. J Immunol 2000 : 165 : 461 472.